4.8 Article

TCF12 is mutated in anaplastic oligodendroglioma

期刊

NATURE COMMUNICATIONS
卷 6, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms8207

关键词

-

资金

  1. program 'Investissements d'avenir' [ANR-10-IAIHU-06]
  2. Genome Quebec
  3. le Ministere de l'Enseignement superieur, de la Recherche, de la Science et de la Technologie (MESRST) Quebec
  4. McGill University
  5. Cancer Research UK [C1298/A8362]
  6. Leukaemia Lymphoma Research
  7. Myeloma UK
  8. Ligue Nationale Contre le cancer
  9. Fondation ARC pour la Recherche sur le Cancer
  10. Institut National de la Sante et de la Recherche Medicale (INSERM)
  11. European Union (FP7-PEOPLE-CIG)
  12. Institut National du Cancer
  13. Cancer Research UK [15116] Funding Source: researchfish

向作者/读者索取更多资源

Anaplastic oligodendroglioma (AO) are rare primary brain tumours that are generally incurable, with heterogeneous prognosis and few treatment targets identified. Most oligodendrogliomas have chromosomes 1p/19q co-deletion and an IDH mutation. Here we analysed 51 AO by whole-exome sequencing, identifying previously reported frequent somatic mutations in CIC and FUBP1. We also identified recurrent mutations in TCF12 and in an additional series of 83 AO. Overall, 7.5% of AO are mutated for TCF12, which encodes an oligodendrocyte-related transcription factor. Eighty percent of TCF12 mutations identified were in either the bHLH domain, which is important for TCF12 function as a transcription factor, or were frameshift mutations leading to TCF12 truncated for this domain. We show that these mutations compromise TCF12 transcriptional activity and are associated with a more aggressive tumour type. Our analysis provides further insights into the unique and shared pathways driving AO.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据